The Convention on Biological Diversity (CBD) is the global response to one of the most pressing environmental problems of our time: the loss of the world’s biological wealth. The CBD’s third objective, access and benefit sharing (ABS), aims at giving incentives for the conservation and sustainable use of biodiversity by adding(economic) value to genetic resources used by industry. The pharmaceutical sector is one of the most prominent commercial users of genetic resources. This thesis answers the question ‘To what extent are pharmaceutical companies voluntarily realising the ABS provisions of the CBD and what can be learned from this a) about the possible role of corporate responsibility in biodiversity governance and b) for the ongoing negotiations on the nature of an international ABS regime?’.
|Uddannelser||TekSam - miljøplanlægning, (Bachelor/kandidatuddannelse) Kandidat|
|Udgivelsesdato||1 jun. 2005|
|Vejledere||Peder Winkel Agger & Tom Whiston|
- pharmaceutical industry
- international regime
- access and benefit sharing
- corporate responsibility